Deucrictibant

In 2024, Angioedema News highlighted top advancements in angioedema treatment, including deals for donidalorsen, NTLA-2002's 95% attack reduction, Takeda's partnerships, Takhzyro's efficacy in adolescents, deucrictibant's Phase 3 trials, FDA's lift on deucrictibant hold, Ionis' FDA application for donidalorsen, garadacimab's safety, Haegarda's real-world effectiveness, and Orladeyo's long-term benefits in Japan.

Pharvaris announces financial results for Q3 2024, highlighting positive long-term extension data for deucrictibant in preventing and treating HAE attacks, plans to initiate CHAPTER-3 Phase 3 study by YE2024, and expansion into AAE-C1INH treatment. The company maintains a strong financial position with €305 million in cash and cash equivalents.

BRAIN Biotech AG secures up to EUR 128.88 million in a royalty monetization deal with Royalty Pharma for deucrictibant, an investigational compound. The deal includes an upfront payment of EUR 18.41 million and potential milestones.

BRAIN Biotech AG secures EUR 128.88 million in royalty monetization for deucrictibant, with EUR 18.41 million upfront and potential milestones of EUR 110.47 million. The deal accelerates the company’s goal to lead in the industrial enzyme market, focusing on food, beverage, and life sciences.

BRAIN Biotech AG concludes royalty monetization deal with Royalty Pharma for up to EUR 128.88 million on investigational pharma compound deucrictibant, receiving an upfront payment of EUR 18.41 million, potential regulatory milestones of up to EUR 18.42 million, and long-term sales related milestones of up to EUR 92.05 million.

Pharvaris plans to initiate a Phase 3 trial, CHAPTER-3, by year-end to test an oral, extended-release tablet of deucrictibant for hereditary angioedema (HAE). The trial aims to assess safety and efficacy in reducing HAE attacks. Pharvaris also intends to pursue deucrictibant's development for acquired angioedema, following promising data from an Amsterdam study. Deucrictibant, designed to block the bradykinin B2 receptor, is available in both extended-release and immediate-release formulations.

Deucrictibant effectively prevents and treats hereditary angioedema (HAE) attacks in clinical trials, with sustained reductions in attack rates and faster symptom relief. Pharvaris is advancing Phase 3 trials for both prophylactic and on-demand treatment formulations.